Benzinga | Sep 16, 2021 12:49PM EDT

Gilead Churns Out Additional Trodelvy Data

* Gilead Sciences Inc (NASDAQ:GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies.

* The results were presented at the European Society of Medical Oncology (ESMO21) Congress 2021.

* The Company said that a sub-analysis from the study showed significant and clinically meaningful improvements in health-related quality of life over the standard of care (SoC).

* Trodelvy received full FDA approval in April to treat metastatic TNBC patients in the second-line or later, in addition to an accelerated OK in urothelial carcinoma the same month.

* Related Content: Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer.

* Among the group of 419 total patients, the 236 who were in the drug arm showed significant and clinically meaningful improvements across the board.

* Trodelvy patients saw improvements in global health status, physical functioning, and emotional functioning, compared to those who received SoC of physician's chemotherapy choice.

* Gilead also said it observed significant improvements in symptomatic impact of fatigue, pain, difficulty breathing, and insomnia.

* Only diarrhea was significantly and meaningfully worse with Trodelvy.

* Price Action: GILD stock is down 0.68% at $71.27 during the market session on the last check Thursday.

* Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)